Skip to main content

Oncology

Open Access Acute Myeloid Leukemia Review

Novel therapeutic targets in AML

Many more targeted therapies are now available for people with AML, in both the newly diagnosed and relapsed/refractory settings. Find out more about the genetic and protein targets, and their associated therapeutics, in this review.

ICI-induced insulin-dependent diabetes without islet autoantibodies

Free for a limited time Diabetes Case Study

Rapidly progressive insulin-dependent diabetes in the absence of islet autoantibodies developed two years after starting treatment with the immune checkpoint inhibitor nivolumab.

Adding pembrolizumab to CRT boosts cervical cancer PFS

27-03-2024 Cervical Cancer News

Women with a new diagnosis of high-risk, locally advanced cervical cancer could benefit from the addition of pembrolizumab to standard chemoradiotherapy.

Profound hypotension induced by ICI treatment

A case of extreme hypotension that could have been prevented or mitigated with awareness of the underlying hypothyroidism related to nivolumab treatment.

Role of ctDNA in gynecologic malignancies

Free for a limited time Gynecologic Cancer Review

Although circulating tumor DNA analysis has not been adopted as widely in gynecologic cancers as in other tumor types, new research shows promise for diagnosis, prognosis, and prediction of recurrence.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Episode 9: The gut microbiome and CAR T-cell therapy

How do nutrition, supplements and antibiotics impact patient outcomes?

Recent research suggests that the gut microbiome could be an important modulator of response to CAR T-cell therapy in patients with hematologic cancers.

Prof. Marion Subklewe takes us through the latest evidence, highlighting the impact of antibiotics, nutrition, and dietary supplements, and discusses how to devise interventions to improve patient outcomes.

Prof. Marion Subklewe

ICI-induced insulin-dependent diabetes without islet autoantibodies

Free for a limited time Diabetes Case Study

Rapidly progressive insulin-dependent diabetes in the absence of islet autoantibodies developed two years after starting treatment with the immune checkpoint inhibitor nivolumab.

Profound hypotension induced by ICI treatment

A case of extreme hypotension that could have been prevented or mitigated with awareness of the underlying hypothyroidism related to nivolumab treatment.

Severe megaloblastic anemia related to erlotinib

Open Access NSCLC Case Study

The first case of severe megaloblastic anemia in a patient treated with erlotinib for advanced NSCLC. It highlights the need for close clinical and blood monitoring in people receiving long-term TKI therapy.

Live Webinar | 10-06-2024 | 16:30 (CEST)

Challenges in advanced CTCL – diagnosis and management

Live: Monday 10 June 2024, from 16:30 – 18:00 (CEST)

In this live interactive webinar, a multidisciplinary team of speakers will provide practical guidance on managing patients with cutaneous T-cell lymphoma. Learn about the key aspects of diagnosis and treatment via a series of patient cases.

Sponsored by: Kyowa Kirin

Developed by: Springer Healthcare

Current Reviews

Recent advances in understanding the biology of follicular lymphoma

Lymphoma Progress in Hematology

Follicular lymphoma (FL), the most common indolent B-cell lymphoma, develops over decades before manifesting as overt disease. BCL2 overexpression by t(14;18) confers a survival advantage to B cells during the germinal center reaction, and …

N1-positive non-small cell lung cancer: surgeons’ perspective before undertaking a major resection

NSCLC Mini Review Article

Among various reasons for a rise in surgical referrals for locally advanced non-small cell lung cancer, few are improved clinical-pathological staging, better understanding of oncological driver mutation, and aggressive neoadjuvant treatment …

Breast Cancer Subtypes: Clinicopathologic Features and Treatment Considerations

Primary breast carcinomas are largely of ductal or lobular histology; however, there are a myriad of other subtypes less commonly seen. While most breast cancers do fit within these two primary groupings, patients may present with unique subtypes …

Glioblastoma stem cell metabolism and immunity

Despite enormous efforts being invested in the development of novel therapies for brain malignancies, there remains a dire need for effective treatments, particularly for pediatric glioblastomas. Their poor prognosis has been attributed to the …

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
NSCLC Podcast

Episode 7: A deep dive into ADAURA

The ADAURA trial has, as of this year, demonstrated an overall survival benefit with the adjuvant use of osimertinib in people with resectable NSCLC. 

We take an in-depth look at the study with Dr. Luis Paz-Ares, who outlines the study findings, discusses the clinical implications, and addresses the pertinent questions raised by the trial.

Dr. Luis Paz-Ares
SPONSORED

Webinar

A series of patient cases underpin this live interactive webinar that aims to provide practical guidance on a multidisciplinary approach to managing patients with cutaneous T-cell lymphoma.

Sponsored by:
  • Kyowa Kirin
Developed by: Springer Healthcare

Webcast | Videos | Cases (Link opens in a new window)

Identifying molecular biomarkers is crucial in determining the best targeted treatment options for your patients with advanced thyroid cancer.

Join our expert-led multi-format educational program that explores the continuing discovery of new genomic targets and delivers the latest research in molecular testing and the application of targeted therapies for thyroid cancer.

Start by watching our webcast and short vodcasts.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME

eLearning | Interviews | Digital Treatment Map (Link opens in a new window)

1.0 AMA PRA Category 1 Credit(s)

Expert-led, multiformat program which will address the individualized management of NSCLC, through education on the detection of NTRK gene fusions, current evidence-based guidelines, and new and emerging therapies. Will also include guidance on integrating shared decision making into your clinical practice, drawing on insights from a patient on how best to communicate.

Supported by:
  • Bayer HealthCare Pharmaceuticals Inc.
Developed by: Springer Healthcare IME

Further Reading

Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis

Open Access Graft-Versus-Host Disease Original Article

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important therapy for patients with T-cell lymphomas, including cutaneous T-cell lymphoma (CTCL), adult T-cell lymphoma (ATL), and peripheral T-cell lymphoma (PTCL).

18F-FDG PET/CT metabolism multi-parameter prediction of chemotherapy efficacy in locally progressive gastric cancer

Open Access Positron Emission Tomography Original Article

In 2022, the World Health Organization ranked the incidence of gastric cancer as third and fifth most in China and worldwide, respectively, with incidence and mortality rates accounting for 10.6% and 12.5% of cancer cases in China, for 5.6% and …

Potential Cause-and-Effect Relationship between Gut Microbiota and Childhood Neuroblastoma: A Mendelian Randomization Analysis

Open Access Neuroblastoma Original Article

Neuroblastoma (NB) is the most common extracranial solid tumor in children and accounts for 15% of childhood cancer-related deaths [ 1 ]. At the time of diagnosis, approximately 50% of patients have lymph node, liver, and bone marrow metastases …

The Importance of Biomarker Testing in the Treatment of Advanced Non-Small Cell Lung Cancer: A Podcast

Open Access Biomarkers Commentary

The identification of actionable biomarkers and development of targeted therapies have revolutionized the field of lung cancer treatment. In patients with advanced non-small cell lung cancer (NSCLC), biomarker testing can inform selection of …

Related topics

Many more targeted therapies are now available for people with AML, in both the newly diagnosed and relapsed/refractory settings. Find out more about the genetic and protein targets, and their associated therapeutics, in this review.

Read more